Mouse pre-microRNA Expression Construct mir-192
- Known as:
- Mouse pre-microRNA Expression Construct mir-192
- Catalog number:
- mmir-192-pa-1
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Sbi systeme bioscience
- Gene target:
- Mouse pre-microRNA Expression Construct mir-192
Related genes to: Mouse pre-microRNA Expression Construct mir-192
- Gene:
- MIR192 NIH gene
- Name:
- microRNA 192
- Previous symbol:
- MIRN192
- Synonyms:
- hsa-mir-192
- Chromosome:
- 11q13.1
- Locus Type:
- RNA, micro
- Date approved:
- 2004-04-23
- Date modifiied:
- 2019-01-18
Related products to: Mouse pre-microRNA Expression Construct mir-192
Related articles to: Mouse pre-microRNA Expression Construct mir-192
- Chronic liver diseases are frequently accompanied by metabolic dysfunction, making precision nutrition relevant for prevention, diagnosis, risk stratification, and management. This review summarizes nutritional omics evidence in hepatology, emphasizing metabolic dysfunction-associated steatotic liver disease as a prevalent model. Nutrigenetics provides information on inherited susceptibility by identifying genetic variation affecting hepatic lipid handling, triglyceride export, phospholipid remodeling, and glucose-driven lipogenesis. Nutrigenomics characterizes transcriptional programs involved in hepatic lipogenesis, inflammation, oxidative stress, and fibrogenesis. Nutriepigenetics captures exposure memory through DNA methylation, histone regulation, and small-RNA signaling, including miR-122, miR-21, miR-34a, and miR-192; diet may modulate this layer through one-carbon metabolism, methyl-donor availability, oxidative stress, acetyl-CoA and NAD+-dependent pathways, and lipid peroxidation. Nutrimetagenomics highlight taxa such as Ruminococcus, Faecalibacterium, Veillonella, Bacteroides, Escherichia, and Klebsiella, but translation requires functional characterization beyond stool taxa. Nutrimetabolomics and lipidomics, including OWL-liver platforms, track dietary adherence, lipid species, bile acids, amino acids, lipoproteins, and biological non-response. Future progress will require AI-supported, phenotype-first integrated models tested in multiethnic longitudinal studies with standardized dietary assessment, biospecimen collection, meaningful liver endpoints, realistic workflows, and adaptive lifestyle-care strategies. - Source: PubMed
Publication date: 2026/09/11
Perez-Diaz-Del-Campo NuriaLopez-Moreno Miguelde Cuevillas BegoñaMartinez-Urbistondo DiegoMartínez J AlfredoRamos-Lopez Omar - Colon cancer (CC) is a leading cause of cancer-related mortality globally. Although chemotherapy remains the primary treatment, its toxicity and drug resistance highlight the need for alternative therapeutic strategies. Silymarin (Sily), a natural compound, and zinc oxide nanoparticles (ZnO-NPs) have shown potential antitumor activity. This study evaluated Sily and/or ZnO-NPs against DMH-induced CC in rats. Thirty male Sprague-Dawley rats were divided into five groups ( = 6): control, CC (DMH 20 mg/kg/16-week S.C.), and three groups receiving Sily (40 mg/kg orally), ZnO-NPs (10 mg/kg IP), or their combination daily for 4 weeks. In comparison to the CC group, Sily or ZnO-NPs significantly decreased CEA levels, restored mucin synthesis, and improved colonic histology, with the combination treatment producing the most pronounced antitumor effects. Treatments attenuated oxidative stress, with Sily restoring SOD and GSH levels, whereas ZnO-NPs primarily reduced lipid peroxidation, as reflected by decreased MDA levels. Mechanistically, the combined therapy decreased inhibitory GSK-3β phosphorylation and β-catenin expression, consistent with restoration of GSK-3β-mediated suppression of β-catenin. The combination also restored PKCα and miR-192 expression and reduced the expression of the proliferation- and metastasis-associated markers MMP-9, c-Myc, and Cyclin-D1. CD133 expression was significantly reduced, suggesting an effect on the cancer stem cell-associated phenotype. Sily and ZnO-NPs demonstrated therapeutic effects against CC, particularly when administered in combination. Their antitumor effects were associated with modulation of miR-192/PKCα and GSK-3β/β-catenin signaling, supporting further investigation of their combined multitargeted potential in CC. - Source: PubMed
Publication date: 2026/09/21
Yousef Eman HMegahed AyaSamy AlaaSalem Amgad EAlamoudi Jawaher AbdullahAbbas AhmedEmbaby Eman M - Type 2 diabetes mellitus (T2DM) is a major driver of chronic kidney disease and cardiovascular morbidity worldwide. Extracellular vesicles (EVs), particularly exosomes, carry microRNAs (miRNAs) that reflect the pathophysiological state of their parent cells and represent promising non-invasive biomarkers. This review comprehensively examines the diagnostic and mechanistic roles of EV-derived miRNAs in diabetic nephropathy (DN) and cardiovascular diseases (CVDs) associated with T2DM. A PRISMA-guided literature search of PubMed, Scopus, Web of Science, and Embase identified 847 articles published between January 2020 and June 2026, of which 156 studies met the inclusion criteria. Several urinary exosomal miRNAs demonstrated significant diagnostic performance for DN, including miR-4534 (AUC = 0.786), miR-136-5p (sensitivity 72.2%, specificity 78.4%), and miR-142-3p. A meta-analysis of circulating miRNAs in diabetic kidney disease reported a pooled AUC of 0.79. In the cardiovascular setting, exosomal miR-155-5p (AUC = 0.901), miR-15a-3p (AUC = 0.874), and a four-miRNA panel (miR-433-3p/let-7b/miR-30-5p/miR-122-5p; AUC = 0.833) demonstrated strong diagnostic performance for ischemic heart disease and carotid atherosclerosis in T2DM. Mechanistically, key EV-associated miRNAs, including miR-21, miR-192, and the anti-fibrotic miR-29 family, participate in fibrosis, inflammation, oxidative stress, endothelial dysfunction, and cardiac remodeling pathways. EV-derived miRNAs therefore represent highly promising non-invasive biomarkers for the early diagnosis and monitoring of diabetic renal and cardiovascular complications. However, clinical translation requires standardized EV isolation and miRNA detection protocols, together with validation in large multicenter prospective cohorts. This review highlights the considerable diagnostic and translational potential of EV-derived miRNAs for precision medicine and liquid biopsy applications in T2DM complications. - Source: PubMed
Publication date: 2026/06/20
Arailym YessenbekovaAbaildayev ArmanAyaz Belkozhayev - Obesity and metabolic dysfunction associated steatotic liver disease (MASLD) are interrelated metabolic disorders characterized by chronic inflammation, insulin resistance, and dyslipidemia. While both conditions are well recognized clinically, the molecular mechanisms underlying their frequent coexistence remain poorly understood. Growing evidence indicates that circulatory exosomal microRNAs (miRNAs) act as critical mediators of inter-organ communication. In this PROSPERO-registered systematic review (CRD420251017335), we integrated clinical evidence with bioinformatics analyses to clarify shared miRNA-mediated regulatory networks between obesity and MASLD. Literature was retrieved from MEDLINE, ISI Web of Science, and Embase. Bioinformatics analysis using miRWalk also revealed shared miRNAs, predicted target genes, and elucidated enriched pathways using Gene Ontology and KEGG. Clinical studies identified 93 obesity-associated and 24 MASLD-associated exosomal miRNAs, with and emerging as common nodes. Bioinformatics analysis using miRWalk revealed extensive overlap at the functional level, including 40,410 shared miRNA-mRNA interactions and 42 common target genes. Several circulating exosomal miRNAs from obese individuals, including , , , and , were consistently associated with liver histopathology, inflammatory markers, and liver enzyme levels. Importantly, obesity-derived , , and showed strong diagnostic performance (AUC ≥ 0.85), exceeding that of alanine aminotransferase (ALT). Furthermore, emerged as a central therapeutic target within the shared miRNA network, regulated by both and , providing a molecular link between adipose tissue dysfunction and hepatic metabolic regulation. This integrative analysis supports a unified model in which exosomal miRNAs serve as key molecular intermediaries connecting obesity and MASLD. - Source: PubMed
Publication date: 2026/05/22
Mo QiguiGhafourian AmirrezaHamdi MasoomehAlidadipour ArianSoleimani MahdiehDavoudi MaryamMiao XiaoleiAfrisham RezaBagherieh Molood - Albuminuria is a widely used clinical marker for diabetic nephropathy (DN); however, its limited sensitivity and specificity in detecting early renal alterations highlight the need for additional indicators. MicroRNAs (miRNAs) are emerging as molecular regulators involved in the pathogenesis of DN and may provide insight into early renal involvement in type 2 diabetes mellitus (T2DM). This study aimed to evaluate the serum expression levels of miR-21 and miR-192 in normo- and microalbuminuric patients with T2DM, and explore their associations with metabolic and renal parameters. - Source: PubMed
Abd Alrahim Nosaiba MAbd Elalim Alshaymaa AFarrag Enas AAbdel-Kareem Shimaa MShaban Sahar SaadEldeenEldamanhory Aya AKasim Sammar AhmedFath Allah Radwa MMayah Fatma IGhamry Aya AAlkhawagah Sabah MKhidr Emad Gamil